



Big pharma is turning to China for the newest drug ideas
, a 22-employee company with operations in Shanghai and San Diego, had been working on its own therapies. By poring over the patents from Western companies, the biotech found clues to improve its drug candidates.Within months, GluBio had made tweaks that produced more powerful and targeted therapies.
It attracted interest from Western companies and sold a stake in February to French drugmaker Sanofi.Molecular glue is a technology that promotes the stickiness of disease-causing proteins, allowing them to be degraded. It promises a way to treat cancers and other diseases that had been considered “undruggable.” The market potential is huge.GluBio was established in 2021 with funding from Chinese venture capitalists to find molecular-glue drugs.
Chief Executive Gang Lu is a native of Shanghai who had gotten a Ph.D. from UCLA, then worked in the U.S.
Read on livemint.com